US 2002/0177575 A1Published application

Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies

OwnerWard Wakeland, Kui Liuinventors

Life of this patent

Estimating the term…

Abstract

The invention relates to the identification of farnesyl-protein transferase (FPT) as a gene that is upregulated in systemic lupus erythematosus (SLE). Given the widespread availability of inhibitors of FPT, the inventors propose to treat the symptoms of SLE using such inhibitors.

Claims30

Dependent claims

A method for treating systemic lupus erythematosus (SLE) comprising administering to a subject suffering from SLE a first inhibitor of farnesyl-protein transferase (FPT).

Dependencies are inferred from the claim text.

Facts

Application: 10/138,724Filed 3 May 2002
Priority: 4 May 2001
Published: 28 Nov 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/407
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with other…
A61K 31/401
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: proline; Derivatives…
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 31/517
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Family

Application60/288,868Us provisional application · filed 4 May 2001
US 2002/0177575 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results